Macrophages and attenuation of inflammation resolution in APOL1 nephropathy
APOL1 肾病中巨噬细胞和炎症消退的减弱
基本信息
- 批准号:10624214
- 负责人:
- 金额:$ 62.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-20 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressAffectAfrican TrypanosomiasisAfrican ancestryAllelesAmericanAnti-Inflammatory AgentsApolipoproteinsApoptoticAttenuatedAutomobile DrivingBiological FactorsBiological ModelsBiologyBlack raceCellsCholesterol HomeostasisChronicChronic Kidney FailureCoculture TechniquesCodeComplexCytokine SignalingDNADevelopmentDiseaseDisease ProgressionEnd stage renal failureEndoplasmic ReticulumFunctional disorderGenesGenetic TranscriptionGenetic studyGenotypeGoalsHealth Care CostsHomeostasisHumanHuman GeneticsImmuneImmune responseImpairmentIn VitroIndividualInflammationInflammatoryInjuryInjury to KidneyInnate Immune ResponseInterferon Type IIInterleukin-10Interleukin-4InvestigationKidneyKidney DiseasesLinkMacrophageMeasuresMediatingMitochondriaModelingMolecular ChaperonesNatural ImmunityPathogenesisPathway interactionsPatientsPhagocytesPhenotypePlayPrimatesProcessProteinsQuality of lifeReactive Oxygen SpeciesResolutionRespirationRiskRisk FactorsRoleSignal TransductionSignaling ProteinSterilityStimulusStressTestingTherapeuticTissuesTransgenic MiceUnited StatesValidationVariantWorkattenuationbiological adaptation to stresscell typecomorbiditydisease phenotypeendoplasmic reticulum stressexperiencegenome editinggenomic locushealth differencehigh riskimmune functionin vivoinduced pluripotent stem cellinhibitorinsightkidney cellkidney fibrosiskidney repairlipid metabolismmetabolic abnormality assessmentmitochondrial dysfunctionmitochondrial metabolismmortalitynovelpathogenpodocyteprotein activationprotein functionresponseresponse to injuryrisk variantsocioeconomicstissue repairtranscriptomics
项目摘要
PROJECT SUMMARY
Individuals who self-identify as Black in the United States experience disproportionately higher rates of
developing chronic kidney disease (CKD) and experiencing CKD progression to end-stage kidney disease
(ESKD). A portion of this health difference is not explained by socioeconomic and traditional risk factors,
necessitating the study of other biological factors contributing to disease pathogenesis. Human genetics studies
have identified and validated two common coding variants in the primate-specific Apolipoprotein L1 (APOL1)
gene that contribute to high rates of proteinuric CKD in patients with African ancestry. These alleles, termed G1
and G2, evolved and became common due to the survival advantage they confer against African
trypanosomiasis. Despite their role in primate innate immunity, not much is known about the role immune cells
such as macrophages, which contribute to kidney injury and repair, play in APOL1 nephropathy.
To address this gap, we propose to use genome-edited induced pluripotent stem cell (iPSC) derived
macrophages and transgenic mice to investigate how G1 and G2 APOL1 alter macrophage function to promote
kidney disease. We focus on the macrophage due to its dual role in innate immune responses to pathogens and
contribution to kidney injury and fibrosis. In preliminary studies, we have generated genome-edited G1 iPSCs
sharing an isogenic background with G0 controls and found that G1 iPSC derived macrophages maintain higher
expression of proinflammatory genes under multiple conditions. Because chronic sterile macrophage
inflammation can drive kidney disease, we are investigating mechanisms by which G1 and G2 APOL1 promote
a sustained proinflammatory macrophage phenotype and maladaptive tissue repair. In various complex diseases
including CKD, resolution of tissue inflammation requires anti-inflammatory reprogramming of immune cells and
clearance of apoptotic cells by macrophages via efferocytosis. Additionally, macrophage inflammation can be
induced by stress or dysfunction of the endoplasmic reticulum (ER), which has been implicated in APOL1 biology
in other cell types. Therefore, we hypothesize that G1 and G2 macrophages undergo impaired anti-inflammatory
reprogramming and inefficient efferocytosis through enhanced ER stress, thereby contributing to non-resolving
kidney inflammation and APOL1 nephropathy. To test this central hypothesis, we will delineate which ER stress
pathways G1 and G2 APOL1 perturb (Aim 1), investigate anti-inflammatory signaling and mitochondrial
dysfunction in the attenuation of reparative reprogramming of G1 and G2 macrophages (Aim 2), and determine
the mechanisms by which G1 and G2 APOL1 impair efferocytosis (Aim 3). The proposed investigations will test
a novel hypothesis that APOL1 risk alleles amplify kidney injury through macrophage dysfunction. Elucidating
the macrophage’s role in APOL1 nephropathy will offer critical insight for developing complementary strategies
to treat APOL1 disease through enhancing macrophage-mediated tissue repair.
项目摘要
在美国,自我认同为黑人的人经历不成比例的高失业率。
发生慢性肾病(CKD)并经历CKD进展为终末期肾病
(ESKD)。这种健康差异的一部分不能用社会经济和传统风险因素来解释,
这就需要研究导致疾病发病的其他生物学因素。人类遗传学研究
已经鉴定并验证了灵长类特异性载脂蛋白L1(APOL1)中的两种常见编码变体
这些基因导致非洲血统患者蛋白尿性CKD的高发病率。这些等位基因被称为G1
和G2,由于它们赋予非洲人的生存优势,
锥虫尽管它们在灵长类动物先天免疫中的作用,但对免疫细胞的作用知之甚少。
例如巨噬细胞,其有助于肾损伤和修复,在APOL 1肾病中起作用。
为了解决这一差距,我们建议使用基因组编辑的诱导多能干细胞(iPSC)衍生的细胞。
巨噬细胞和转基因小鼠研究G1和G2 APOL 1如何改变巨噬细胞的功能,
肾病由于巨噬细胞在对病原体的先天免疫反应中的双重作用,
导致肾损伤和纤维化。在初步研究中,我们已经产生了基因组编辑的G1 iPSCs,
与G0对照共享同基因背景,并发现G1 iPSC衍生的巨噬细胞维持更高的
在多种条件下促炎基因的表达。因为慢性不育的巨噬细胞
炎症可以驱动肾脏疾病,我们正在研究G1和G2 APOL 1促进
持续的促炎巨噬细胞表型和适应不良的组织修复。在各种复杂的疾病中
包括CKD,组织炎症的消退需要免疫细胞的抗炎重编程,
巨噬细胞通过吞噬作用清除凋亡细胞。此外,巨噬细胞炎症可以是
由内质网(ER)的应激或功能障碍诱导,这与APOL 1生物学有关
其他细胞类型。因此,我们假设G1和G2巨噬细胞经历受损的抗炎作用,
通过增强的ER应激重编程和无效的胞浆细胞增多,从而导致非消退性
肾脏炎症和APOL 1肾病。为了验证这一中心假设,我们将描述哪种ER应激
途径G1和G2 APOL 1干扰(目的1),研究抗炎信号传导和线粒体
G1和G2巨噬细胞修复性重编程衰减功能障碍(目的2),并确定
G1和G2 APOL 1损害红细胞增多症的机制(目的3)。拟议的调查将测试
一种新的假说,即APOL1风险等位基因通过巨噬细胞功能障碍放大肾损伤。阐明
巨噬细胞在APOL1肾病中的作用将为开发补充策略提供重要的见解
通过增强巨噬细胞介导的组织修复来治疗APOL 1疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jennie J LIn其他文献
Jennie J LIn的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jennie J LIn', 18)}}的其他基金
Macrophages and attenuation of inflammation resolution in APOL1 nephropathy
APOL1 肾病中巨噬细胞和炎症消退的减弱
- 批准号:
10345803 - 财政年份:2022
- 资助金额:
$ 62.76万 - 项目类别:
Modulation of Macrophage Function through Alternative Splicing in Cardiometabolic Diseases
通过选择性剪接调节心脏代谢疾病中的巨噬细胞功能
- 批准号:
9547928 - 财政年份:2017
- 资助金额:
$ 62.76万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 62.76万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 62.76万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 62.76万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 62.76万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 62.76万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 62.76万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 62.76万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 62.76万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 62.76万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 62.76万 - 项目类别:
Research Grant